Bhimar’s Post

#ColorectalCancer | A malignancy that originates in the colon or rectum, typically developing from precancerous polyps. Let's talk about colorectal cancer, a disease that affects millions worldwide. Colorectal cancer starts as a small, non-cancerous (benign) lump of cells on the inner lining of the colon or rectum known as a polyp. Some polyps may eventually develop into cancer. Depending on where the cancer begins, it may also be called rectal cancer or colon cancer. Depending on the size and location of the tumor, different symptoms may present at different times. The diagnosis of colorectal cancer is made using various tests. When selecting a diagnostic test, several aspects are taken into account, such as the type of cancer suspected, the symptoms, age and general health, medical and family history, and the outcomes of former medical tests. For deeper insights, visit our website @ https://lnkd.in/dSR4XeFn to explore groundbreaking research on colorectal cancer and discover more about this critical topic. #ColorectalCancerResearch #StayInformed #ColorectalCancerAwareness #EarlyDetectionSavesLives #HealthyLifestyle #ColorectalCancerSymptoms #ColorectalCancerCauses #ColorectalCancerDiagnosis #ColorectalCancerManagement #Colonoscopy #RectalCancer #ColonCancer #Ultrasonography #ComputedTomography #MagneticResonanceImaging #Biopsy #Bhimar #LifeSciences #Healthcare #Informations #Omics #Oncology #Neurology

Cancer, a formidable adversary to human health, has spurred the development of a range of therapies over the years. Conventional approaches such as chemotherapy, radiation therapy, hormone therapy, and immunotherapy are known to prolong the lives of cancer patients. However, it’s becoming increasingly clear that these treatments, while offering some benefits, often come at the cost of toxic side effects and limited success rates, especially in late-stage cancers. As the medical community continues to explore new horizons, emerging technologies offer promising alternatives that could reshape the way we approach cancer treatment. In this article, we’ll delve into the limitations of conventional cancer therapies, explore the potential of early-stage detection methods, and highlight the significance of innovative approaches like oncolytic virus therapy and minimally invasive surgery. 📚 Read more in our blog post and leave a comment! 🌐 https://lnkd.in/dNUKYsHB #virotherapy #cancerawareness #cancerprevention #modernmedicine #healthchallenge

Accuracy of ICG compared with technetium-99 m for sentinel lymph node biopsy in vulvar cancer Purpose: Sentinel lymph node biopsy with radioactive tracer is the standard-of-care in lymph node status assessment in vulvar cancer. Indocyanine green fluorescence-ICG is a promising detection method, due to its advantages over technetium-99 m. In vulvar cancer, the procedure is controversial due to study heterogeneity and the small sample size in previous studies. This study evaluates ICG sentinel lymph node detection compared with the criterion-standard with technetium (dual modality method). Methods: Preoperative technetium and intraoperative ICG for sentinel lymph node have been prospectively evaluated in early-stage vulvar cancer. The primary endpoint was to determine accuracy in the detection rate for ICG compared with technetium. Secondary objectives included tracer modality relationship with obesity, tumor size and location. Results: In total, 75 patients participated at 8 centers; 38 had lateral and 37 had midline vulvar tumors. The overall sentinel lymph node detection rate was 85.3 % for technetium and 82.7 % for ICG. For lateral tumors, the detection rate was 84.2 % vs. 89.5 %, while it was 86.5 % vs. 75.7 % for middle tumors, using technetium and ICG, respectively. The median sentinel node harvest was 1.7 (range 1-4), with 24 % metastatic involvement. The sensitivity and positive predictive value for ICG based on the standard technique with technetium was 91.08 % (95 % CI, 83.76-95.84) and 94.8 % (95 % CI, 84.84-96.48), respectively. No significant differences were found comparing the two tracers in patients with midline lesions, obesity (body mass index ≥ 30) and tumor size ≥ 2-4 cm. Conclusion(s): ICG shows comparable performance parameters to the gold-standard of radioisotope localization. Alberto Rafael Guijarro Campillo Pablo Padilla-Iserte, Barbara Couso, Diego Erasun Jesus Utrilla-Layna octavio arencibia ANA BOLDO RODA Juan Gilabert-Estellés, Nadia Veiga, Victor Lago José Miguel Cárdenas Rebollo Santiago Domingo https://lnkd.in/exTaFUWr #ICG #indocyaninegreen #fluorescent #fluorescence #guidedsurgery #surgery #surgeons #imaging #thinkgreen #Cancer #patients #tumor

Dr. Poonam Patil, Consultant - Medical Oncology, Manipal Hospital Old Airport Road, elaborates on preventive chemotherapy following Kate Middleton's cancer diagnosis. This treatment is applied after surgery to eliminate residual cancer cells that may remain undetected, reducing the risk of cancer recurrence. It involves potent anti-cancer drugs administered orally or intravenously in multiple treatment cycles. Read this article to learn more about preventative chemotherapy as a treatment option. #ManipalHospitalOldAirportRoad #YourManipal #LifesOn #Healthcare #Chemotherapy #Oncology

A Noteworthy Review---Just Published👇 📢 Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment ------------------------- 📖 This review provides a detailed overview of the current understandings behind the mechanisms of MDSC-mediated suppression of anti-tumour immunity, and discusses potential strategies to target MDSC immunosuppressive mechanisms to overcome therapeutic resistance. 🖊 This study by Eric Jou* , Natasha Chaudhury and @Fizza Nasimet has demonstrated that MDSCs play critical roles in eliciting therapeutic resistance against all major modes of cancer treatment including surgery, chemotherapy, radiotherapy and immunotherapy through a combination of immunosuppressive mechanisms. Increasing understanding of MDSC immunosuppressive mechanisms have proved invaluable in opening avenues for the development of potential targeting strategies against MDSCs by limiting their downstream effector function. 🍸 Enjoy reading！ https://lnkd.in/ghyMsQmV #TumorMicroenvironment #CancerTherapy #PreclinicalModels #Immunotherapy #myeloid-derived #suppressor #cell #MyeloidCells #Immunosuppression

▶ This article belongs to our special issue Novel Strategies and Targets for Immunotherapy of Cancer.

🚀 Groundbreaking news for lung cancer treatment! 👉 Stay informed & read the full article now - https://bit.ly/4ekRRQt 🧬 Immunotherapy before & after surgery reduces death risk & disease recurrence. 🔬 This new approach could redefine lung cancer outcomes. 💪 Offering hope to patients and healthcare providers alike. Dive into the latest research on improved survival rates. Credit: The Johns Hopkins University #LungCancer #Immunotherapy #chemotherapy #Healthcare #Oncology #Medicine #meded #eMednews

Thrilled to be featured on 𝐏𝐬𝐲𝐜𝐡𝐫𝐞𝐠 in their article "𝐒𝐭𝐨𝐦𝐚𝐜𝐡 𝐂𝐚𝐧𝐜𝐞𝐫 𝐚𝐧𝐝 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭" Stomach cancer treatment typically involves a combination of surgery, chemotherapy, and radiation therapy, depending on the cancer's stage and location. Surgical options may include partial or total gastrectomy, where part or all of the stomach is removed. 𝐂𝐡𝐞𝐦𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 uses drugs to target and kill cancer cells, and may be administered before surgery (neoadjuvant) to shrink the tumor or after surgery (adjuvant) to eliminate remaining cancer cells. Radiation therapy uses high-energy beams to destroy cancer cells and may be used in conjunction with surgery and chemotherapy. Targeted therapies and immunotherapies are emerging treatments that focus on specific genetic mutations or enhance the body's immune response to cancer. Early detection and a multidisciplinary approach are crucial for effective management and improved outcomes. The stomach cancer treatment market is expanding due to rising incidence rates and advancements in medical technology. As per the 𝐆𝐫𝐨𝐰𝐭𝐡 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬, The 𝐬𝐭𝐨𝐦𝐚𝐜𝐡 𝐜𝐚𝐧𝐜𝐞𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐦𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 was valued at around 𝐔𝐒𝐃 𝟒.𝟐𝟐 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟐 and is estimated to reach 𝐔𝐒𝐃 𝟏𝟏.𝟗𝟔 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟏, expanding at a 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟏𝟑.𝟏% during the forecast period, 𝟐𝟎𝟐𝟑-𝟐𝟎𝟑𝟏 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 𝐚𝐭: https://lnkd.in/dknQmpf3 #stomachcancer #cancer #stomachcancertreatment #technology #medical #data #analysis #research #reports #growthmarketreports

Prostate cancer screening and treatment: from PSA to PSMA. Are we now at the verge of re-introducing such screening programs for all or looking at risk-based assessment ? “A risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is considered, a combination of targeted and regional biopsies should be performed. Prostate-specific membrane antigen positron emission tomography imaging is the most sensitive technique for identifying metastatic spread. Active surveillance is the appropriate management for men with low-risk PCa, as well as for selected favourable intermediate-risk patients with International Society of Urological Pathology grade group 2 lesions.”

𝐇𝐈𝐆𝐇𝐋𝐈𝐆𝐇𝐓𝐈𝐍𝐆 𝐆𝐑𝐎𝐔𝐍𝐃𝐁𝐑𝐄𝐀𝐊𝐈𝐍𝐆 𝐑𝐄𝐒𝐄𝐀𝐑𝐂𝐇 𝐎𝐍 𝐂𝐃3+ 𝐓𝐈𝐋𝐒 𝐈𝐍 𝐂𝐎𝐋𝐎𝐑𝐄𝐂𝐓𝐀𝐋 𝐂𝐀𝐍𝐂𝐄𝐑 I came across a fascinating longitudinal study published in The Lancet by Luigi Laghi and colleagues, which investigates the role of CD3+ tumor-infiltrating lymphocytes (TILs) at the invasive margin of colorectal cancer and their impact on post-surgical metastasis. 𝐒𝐭𝐮𝐝𝐲 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰: The research assessed the relationship between the density of CD3+ TILs and the occurrence of distant-organ metastases after surgery in a cohort of 286 patients with deeply invading (pT3 or pT4) and microsatellite instability (MSI)-typed colorectal cancer. The study was conducted at the IRCCS Istituto Clinico Humanitas in Milan, Italy, from 1997 to 2004. 𝐊𝐞𝐲 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬: 🔹CD3+ TIL density was significantly higher in MSI colorectal cancers compared to mismatch repair-system-proficient tumors (6.53% vs 2.19%; p<0.0001). 🔹Higher densities of CD3+ TILs were associated with a lower risk of metachronous metastasis, particularly in node-negative (stage II) colorectal cancer patients. 🔹Specifically, a CD3+ TIL density greater than 5% markedly reduced the risk of metastasis (HR 0.06, 95% CI 0.01-0.48, p=0.008). 🔹Conversely, no significant association was found between CD3+ TIL density and metastasis risk in node-positive (stage III) colorectal cancer patients. 🔹High CD3+ TIL densities were linked to better disease-specific survival (DSS) and disease-free survival (DFS) in node-negative patients. 𝐈𝐦𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬: This study underscores the importance of CD3+ TILs as a prognostic marker in node-negative colorectal cancer. High densities of CD3+ TILs at the invasive margin could potentially guide clinical decisions, allowing for more tailored post-surgical treatments. However, in node-positive patients, CD3+ TIL densities do not provide the same predictive value, emphasizing the complexity of tumor-immune interactions and the need for further research. 𝐂𝐨𝐧𝐜𝐥𝐮𝐬𝐢𝐨𝐧: The findings suggest that while CD3+ TIL densities can be a useful prognostic tool for stage II colorectal cancer, they should not replace the tumor-node-metastasis classification system for stage III cancers. This study provides a significant contribution to understanding the immune landscape of colorectal cancer and its implications for patient management. 𝐅𝐨𝐨𝐝 𝐟𝐨𝐫 𝐓𝐡𝐨𝐮𝐠𝐡𝐭: How do varying densities of CD3+ TILs specifically interact with different genetic mutations in colorectal cancer to influence long-term patient outcomes? #ColorectalCancer #Immunology #CancerResearch #TheLancet #MedicalResearch #TILs #Oncology #ClinicalOutcomes